转自：前瞻产业研究院 行业主要上市公司：雍禾医疗(02279.HK)、仙琚制药(002332)、*ST 美谷(000615)、益盛药业(002566)、 振东制药(300158)、国际医学(000516)、康惠制药(603139)、康缘药业(600557)、康恩贝(600572)、福瑞 达(600223)等 本文核心数据：中国毛发医疗行业竞争派系;中国植发行业竞争梯队;中国生发药品行业竞争梯队;中国网 上药店终端米诺地尔销售TOP5 从中国毛发医疗行业竞争派系看，雍禾植发、大麦微针植发、青逸植发等布局植发医疗服务，三生制 药、振东制药、仙琚制药等布局医疗养固服务。 中国毛发医疗行业竞争梯队 植发机构方面，第一梯队主要为头部全国连锁龙头，包括雍禾植发、碧莲盛植发、大麦微针植发等，市 场份额合计占比较高，且均具备全国性直营连锁布局、成熟技术体系和强品牌认知度。 中国毛发医疗行业竞争派系 在生发药品领域，第一梯队包括三生制药、振东制药、默沙东等，三生制药、振东制药在米诺地尔市场 占据主要份额，默沙东是非那雄胺的原研药企，具有重要地位;第二梯队包括仙琚制药、康恩贝、厦门 美商医药等，近年来加快推出米诺地尔、非那雄胺等 ...

文/华夏大健康研究院 11月21日下午，由华夏时报社主办的"2025第五届华夏大健康产业发展暨康复服务大会"在北京成功举 行。本次大会以"智领健康未来"为主题，汇聚产业界、学术界、研究机构及投资方等多方代表，旨在整 合全链条资源，把脉行业趋势，探索发展路径。 现场设置了多场高水平圆桌对话，聚焦创新药、脑机接口、AI医疗、中医药转化等前沿议题，深入探 讨行业热点与突破方向。会议还集中发布并展示了一批具有示范意义与前瞻价值的创新典型案例，涵盖 赋能美好生活、ESG、创新药、中医药、生物科技、AI医疗、硬核科技与社会心理服务等八大类别，从 企业实践、技术应用、品牌建设与人物故事等多维度，展现了大健康领域的活力、深度与创新成果。 USANA葆婴：以科学之力，筑健康大家庭 USANA葆婴始终以"成为世界上最健康的大家庭"为愿景，从科学研发到产品质量，从体重管理到母婴 关怀再到全民健康，每一步都彰显着品牌对"美好生活"的深刻理解与务实行动。USANA葆婴将健康理 念融入产品设计，所有保健食品均获得国家注册或备案凭证，原料优质安心，生产过程严格遵循保健食 品GMP规范。这种对质量的执着追求，让USANA葆婴连续多年获得"消 ...

Core Insights - A hair loss treatment product from Mandi International, a subsidiary of Sangfor Pharmaceutical, is set to go public on the Hong Kong Stock Exchange, potentially marking the third IPO for the Liu family [1] - Mandi International holds a significant 57% market share in China's hair loss medication market, driven by its flagship product, Mandi® Minoxidil [1][4] - Despite strong financial performance, Mandi International faces challenges such as product concentration, reduced R&D investment, and increasing competition [1][7] Financial Performance - Mandi International's revenue projections for 2022 to 2024 are 982 million RMB, 1.228 billion RMB, and 1.455 billion RMB, with net profits of 202 million RMB, 441 million RMB, and 309 million RMB respectively [2] - In the first half of 2025, the company reported revenue of 743 million RMB, a 20.2% increase year-on-year, and a net profit of 174 million RMB, up 64.1% [2] - The gross margin for the company has remained high, with figures of 80.3%, 82.0%, 82.7%, and 81.1% from 2022 to 2025 [3] Product Structure - Over 90% of Mandi International's revenue comes from the Mandi® product line, with the core product Mandi® 5% Minoxidil accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [4] - The company is expanding its product line to include other skin care products and is developing a long-acting GLP-1 receptor agonist for weight management, currently in Phase III clinical trials [6] R&D and Marketing - Mandi International's R&D expenses saw a significant drop from 92.2 million RMB in 2024 to 19.5 million RMB in the first half of 2025, raising concerns about its innovation capabilities [7] - In contrast, sales expenses have increased, reaching 374 million RMB in the first half of 2025, which is over 50% of total revenue [9] Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space [12] - Mandi International's core patents are set to expire in 2028, which could lead to a surge in generic products and price competition [12] - The number of registered hair loss shampoos in China has exceeded 400, indicating a crowded market [12] Industry Trends - The global hair loss medication market is projected to reach $2.11 billion in 2024 and $3.175 billion by 2031, with a CAGR of 6.1% [12] - The rising interest in consumer healthcare and the potential for high-margin, self-purchased products are attracting capital market attention [13]

Core Viewpoint - A hair loss treatment product from Mandi International, a subsidiary of 3SBio, is expected to lead to a third IPO for the Liu family, amidst a growing hair loss crisis in China, where over 330 million people are affected, with more than 60% under the age of 35 [2][4]. Financial Performance - Mandi International reported impressive financial data, with revenues projected to reach RMB 9.82 billion, RMB 12.28 billion, and RMB 14.55 billion from 2022 to 2024, and net profits of RMB 2.02 billion, RMB 4.41 billion, and RMB 3.09 billion respectively [6]. - In the first half of 2025, the company achieved revenue of RMB 7.43 billion, a year-on-year increase of 20.2%, and a net profit of RMB 1.74 billion, up 64.1% [6]. Product Concentration - Over 90% of Mandi International's revenue comes from the Mandi® product series, with the core product, Mandi® 5% Minoxidil solution, accounting for 91.3% and 91.6% of revenue in 2022 and 2023 respectively [7][8]. R&D and Marketing Expenditure - Despite strong performance, Mandi International's R&D spending saw a significant drop from RMB 9.22 million in 2024 to RMB 1.95 million in the first half of 2025, raising concerns about its innovation capabilities [11]. - Sales expenses have increased significantly, with over 50% of revenue in the first half of 2025 allocated to sales costs, indicating rising customer acquisition costs in a competitive market [13][14]. Market Competition - The hair loss treatment market is becoming increasingly competitive, with major players like Merck and Johnson & Johnson entering the space. The global market for hair loss treatment is projected to reach USD 2.11 billion in 2024, growing at a CAGR of 6.1% [18]. - Mandi International faces potential risks as some of its core patents are set to expire in 2028, which could lead to a flood of generic products and price wars [18]. Industry Trends - The rising incidence of hair loss among younger demographics is transforming "hair health" into a significant consumer pharmaceutical category, attracting capital market interest [19]. - The company's ability to innovate and diversify its product pipeline will be crucial for its future growth potential, especially in a market that has shown clear demand [19].

Core Insights - The collaboration between 欧加隆, 京东健康, and 雍禾医疗 aims to create a comprehensive hair health management ecosystem that includes online medication purchasing, health consultations, and offline specialized treatments for hair loss patients [1][3][4] - There is a significant demand for systematic and accessible hair health management in China, with approximately 250 million hair loss patients, particularly among younger demographics [3] - The partnership seeks to leverage each company's strengths in online platforms, digital technology, and professional services to enhance patient care and create a patient-centered service model [3][4] Company Contributions - 欧加隆 provides a comprehensive treatment plan for hair health, including both oral and topical solutions, and aims to connect quality resources and build a health ecosystem [3] - 京东健康 is enhancing its digital healthcare ecosystem by launching specialized hair clinics and offering standardized management services that cover the entire patient journey, from initial assessment to follow-up care [3] - 雍禾医疗 has established a standardized treatment service system in the hair health sector and focuses on innovative techniques for hair loss prevention and treatment [3][4] Industry Trends - The hair health management industry is shifting from traditional hair transplant services to a more diversified, personalized, and technology-driven approach [4] - The collaboration reflects a growing trend in the healthcare industry towards integrated services that combine online and offline resources to improve patient outcomes [3][4]

Core Insights - The hair health service industry in China is experiencing rapid growth, yet the leading company, Yonghe Medical, is facing a decline in performance, highlighting a stark contrast to the booming market potential [1][4]. Industry Overview - The Chinese hair health market has expanded from 58.29 billion RMB in 2020 to 79.55 billion RMB in 2023, with projections to reach 116.54 billion RMB by 2028 [2]. - The hair transplant market is expected to grow at an annual rate of nearly 30%, with a forecasted market size of over 30.4 billion RMB by 2028 [2]. Market Demand - A significant driver of market growth is the large population suffering from hair loss, which reached 250 million in 2020, with a market penetration rate of only 0.21% for hair transplant surgeries [3]. - The number of hair loss patients is projected to exceed 343 million by 2026, indicating a substantial supply-demand gap [3]. Company Performance Challenges - Yonghe Medical's revenue has declined by 4.22% year-on-year, with a drop in average spending per customer from 22,987 RMB to 19,761 RMB for hair transplant services [5]. - The company has experienced a significant loss of talent, with the number of doctors decreasing from 350 to 242, a drop of over 30% [6]. Marketing and Operational Efficiency - Yonghe Medical has struggled with high marketing costs, spending 3.81 billion RMB in the first half of 2025, which has not translated into effective customer acquisition [9]. - The company has seen stagnation in store expansion, with only a slight increase in the number of medical institutions from 54 to 63 since its IPO [10]. Strategic Directions - The company aims to tap into the low-ticket hair care service market to create a high-frequency consumption model, potentially increasing the revenue share of medical-grade hair care services to over 50% in the next three years [12]. - There is a focus on the female market, with strategies to cater to aesthetic needs and enhance service quality to attract more female customers [14]. - Yonghe Medical plans to address the younger demographic by offering early intervention products for initial hair loss, which could help build long-term customer relationships [15]. - The company is considering price adjustments and subsidies to lower consumer barriers and enhance market penetration [16]. - Optimizing store layouts and marketing strategies is essential to improve operational efficiency and reduce reliance on high-cost traditional marketing [17][18].

Core Insights - The establishment of the Hair Medicine Professional Committee by the China Non-Public Medical Institutions Association marks a significant step towards the standardization and professional development of hair medicine in China [1][3] Group 1: Committee Formation and Leadership - The Hair Medicine Professional Committee is the 93rd branch of the China Non-Public Medical Institutions Association, with key leadership positions filled by prominent figures in the field [1] - Jiang Wenjie, Director of the Hair Transplant Center at the Chinese Academy of Medical Sciences, was elected as the committee chair, while Zhang Yu, founder and chairman of Beijing Yonghe Medical Technology Group, was elected as the executive vice-chairman and secretary-general [1][3] Group 2: Objectives and Focus Areas - The committee aims to establish a standardized diagnosis and treatment system, promote the implementation of industry standards, and develop clinical guidelines and quality control systems [3] - It will also focus on fostering interdisciplinary collaboration and research innovation, including the establishment of a special research fund and enhancing data-driven applications [3] - Expanding international perspectives and cross-industry cooperation is another key focus, with plans for international academic exchanges and public education initiatives [3] Group 3: Industry Context and Support - Hair loss is increasingly recognized as a health issue rather than merely a cosmetic concern, impacting self-esteem and mental health [4] - Yonghe Medical, a key player in the hair medical field, emphasizes a patient-first approach and has established multiple hair medical institutions across the country, serving hundreds of thousands of patients [4] - The inaugural academic annual meeting of the committee gathered over 400 experts and representatives from the hair medicine field to discuss the latest research, clinical techniques, and future development directions [4]

Core Insights - The establishment of the Hair Medicine Professional Committee by the China Non-Public Medical Institutions Association aims to address challenges in the hair medicine field, including inconsistent diagnostic standards, insufficient professional talent, uneven distribution of technical resources, and imbalanced development of medical service institutions [2][3] - The committee will focus on three key areas: creating a standardized diagnostic system, promoting interdisciplinary integration and research innovation, and expanding international collaboration and cross-industry cooperation [2][3] Group 1 - The Hair Medicine Professional Committee was officially established in Beijing on October 26, marking the 93rd branch of the China Non-Public Medical Institutions Association [2] - The committee's formation is a response to industry needs, aiming to integrate quality resources and promote the standardization and professional development of hair medicine [2] - The committee will facilitate academic exchanges, technical promotion, standard formulation, and talent cultivation to enhance the overall management level and service capability of the hair medicine industry [2] Group 2 - The committee's future work will include developing clinical guidelines and technical specifications, establishing a quality control system, and exploring certification systems for hair medicine technicians in non-public medical institutions [2] - The committee will also focus on building a platform for industry-academia-research transformation, establishing special research funds, and enhancing data-driven and digital applications to improve diagnostic accuracy [2] - The inaugural academic annual meeting of the committee gathered over 400 experts, scholars, and industry representatives to discuss the latest research, clinical techniques, and future development directions in hair medicine [3]

Core Points - The establishment of the Hair Medicine Professional Committee by the China Non-Public Medical Institutions Association aims to address challenges in the hair medicine field, including inconsistent treatment standards and insufficient professional talent [1][2] - The committee will focus on three key areas: building a standardized treatment system, promoting interdisciplinary collaboration and research innovation, and expanding international cooperation [2] Group 1 - The Hair Medicine Professional Committee was officially established in Beijing, with key leadership positions filled by prominent figures in the field [1] - The committee's formation is a response to the rapid development of the hair medicine sector, which still faces multiple challenges [1] - The committee aims to enhance the overall management level and service capacity of the industry, while maintaining its reputation [1] Group 2 - Future work will include creating clinical guidelines and quality control systems, as well as exploring certification for hair medicine technicians in non-public medical institutions [2] - The committee will establish a platform for industry-academia-research collaboration and set up special research funds to accelerate the transformation of research outcomes [2] - The focus will also be on organizing international academic exchanges and promoting public education on "hair health management" [2]

Core Insights - The article discusses the resilience of companies in the Chinese market during economic fluctuations from 2022 to 2025, highlighting the contrasting fates of those that thrived versus those that faltered [1] Company Performance - Yonghe Medical reported a revenue of approximately 860 million yuan in the first half of the year, with a gross profit of about 550 million yuan, marking a 3.9% increase year-on-year [4] - The company achieved a net profit of approximately 27.9 million yuan, recovering from a loss of about 140 million yuan in the same period last year [4] Strategic Advantages - Yonghe Medical's core advantages include its scale as the largest hair transplant company in China and its medical expertise, particularly in FUE technology [5][6] - The company has a professional medical team of 1,320 members, including 226 doctors, making it the largest team in the hair transplant industry [6][8] Operational Improvements - Yonghe Medical has shifted from aggressive expansion to a more cautious approach in opening new stores, particularly in lower-tier cities, to optimize its resources [5][10] - The company has developed a "He Fan" chain medical management system and a "Heaven, Earth, and People" three-network model to enhance operational efficiency [10][12] Future Growth Opportunities - Yonghe Medical anticipates significant growth in the female hair aesthetics market, predicting that it will account for a substantial portion of the industry revenue in the coming years [14][15] - The company has established a comprehensive brand matrix to cater to diverse consumer needs, including partnerships with institutions for new product development targeting female consumers [16] Market Context - The total population suffering from hair loss in China exceeds 250 million, with a significant portion being young individuals facing various pressures [16] - The hair transplant market in China is projected to exceed 116.5 billion yuan by 2028, indicating a growing demand for comprehensive hair health management solutions [16][19]